Zobrazeno 1 - 3
of 3
pro vyhledávání: '"H Alabort Ayllón"'
Autor:
H Alabort Ayllón, J Marco del Rio, J. M. Collado Sanz, JL Sánchez Serrano, M Sáez Garrido, B Serna Serrano, C Del Pozo Carlavilla, S Ruiz Sánchez, E Tebar Martínez, C García Gómez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Baricitinib is an immunosuppressive agent included as one of the therapeutic options for COVID-19 in the Spanish protocol Agencia Espanola del Medicamento y Productos Sanitarios. Aim and objectives The objective was to asses
Autor:
S Plata Paniagua, E Tebar Martínez, H Alabort Ayllón, M Del Pozo Carlavilla, M Sáez Garrido, M Clemente Andújar, S Ruiz Sánchez, J. M. Collado Sanz, B Serna Serrano, C Del Pozo Carlavilla
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab (TCZ) is an immunosuppressor drug, IL-6 inhibitor, indicated for the treatment of rheumatoid arthritis and cytokine release syndrome associated with CAR T cell therapy. It was proposed as a compassionate treatmen
Autor:
M Clemente Andújar, B Serna Serrano, S Ruiz Sánchez, H Alabort Ayllón, C Del Pozo Carlavilla, M Sáez Garrido, S Plata Paniagua, E Tebar Martínez, M Del Pozo Carlavilla, CS Juan Manuel
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab (TCZ) is an immunosuppressor drug, IL-6 inhibitor, indicated for the treatment of rheumatoid arthritis and cytokine release syndrome associated with CAR T cell therapy It was proposed as a compassionate treatment